@article{c5e08a0d69fd463b8216a54821b170d3,
title = "Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma",
abstract = "Although therapeutic options for patients with advanced renal cell carcinoma (RCC) have increased in the past decade, no biomarkers are yet available for patient stratification or evaluation of therapy resistance. Given the dynamic and heterogeneous nature of clear cell RCC (ccRCC), tumor biopsies provide limited clinical utility, but liquid biopsies could overcome these limitations. Prior liquid biopsy approaches have lacked clinically relevant detection rates for patients with ccRCC. This study employed ccRCC-specific markers, CAIX and CAXII, to identify circulating tumor cells (CTC) from patients with metastatic ccRCC. Distinct subtypes of ccRCC CTCs were evaluated for PD-L1 and HLA-I expression and correlated with patient response to therapy. CTC enumeration and expression of PD-L1 and HLA-I correlated with disease progression and treatment response, respectively. Longitudinal evaluation of a subset of patients demonstrated potential for CTC enumeration to serve as a pharmacodynamic biomarker. Further evaluation of phenotypic heterogeneity among CTCs is needed to better understand the clinical utility of this new biomarker.",
keywords = "biomarkers, circulating tumor cells, clear cell renal cell carcinoma, exclusion-based sample preparation, pharmacodynamic, prognostic",
author = "Bade, {Rory M.} and Schehr, {Jennifer L.} and Hamid Emamekhoo and Gibbs, {Benjamin K.} and Rodems, {Tamara S.} and Mannino, {Matthew C.} and Desotelle, {Joshua A.} and Erika Heninger and Stahlfeld, {Charlotte N.} and Sperger, {Jamie M.} and Anupama Singh and Wolfe, {Serena K.} and Niles, {David J.} and Waddah Arafat and Steinharter, {John A.} and {Jason Abel}, E. and Beebe, {David J.} and Wei, {Xiao X.} and McKay, {Rana R.} and Choueri, {Toni K.} and Lang, {Joshua M.}",
note = "Funding Information: David J. Beebe and Joshua M. Lang hold equity in Salus Discovery LLC, which has licensed technology utilized in the manuscript. D. J. Beebe holds equity in Tasso, Inc., Stacks for the Future, LLC, and Bellbrook Labs, LLC. Rana R. McKay is a consultant/Advisory Board Member for Bristol‐Myers Squibb, Dendreon, Exelixis, Janssen, Pfizer, Novartis, and Tempus; receives institutional research funding from Bayer and Pfizer. Xiao X. Wei receives institutional research funding from Bristol‐Myers Squibb. Funding Information: We thank the staff of the University of Wisconsin Carbone Cancer Center (UWCCC) Flow Cytometry Laboratory and the Circulating Biomarker Core shared resources for their valuable contributions to this research. Shared research services at the UWCCC are supported by Cancer Center Support Grant P30 CA014520. BD LSR Fortessa, Grant#: 1S100OD018202‐01, Project Title: Special BD LSR Fortessa. This work was supported by awards from the Wisconsin Partnership Program and Prostate Cancer Foundation Young Investigator Award to J.M. Lang, NIH Grant #1R01CA181648 to S.M. Berry and J.M. Lang, NIH Grant #5R33CA137673 to D.J. Beebe, NSF GRFP DGE‐0718123 to D.J. Beebe, University of Wisconsin Carbone Cancer Center Support Grant P30 CA014520. Publisher Copyright: {\textcopyright} 2021 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.",
year = "2021",
doi = "10.1002/1878-0261.12931",
language = "English (US)",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
}